Novo Nordisk to build new insulin production plant in Brazil

Published: 7-Nov-2003

Danish company Novo Nordisk is to invest more than US$200m (Euro 175m) in the construction of a new insulin production plant in the City of Montes Claros, Brazil.


Danish company Novo Nordisk is to invest more than US$200m (Euro 175m) in the construction of a new insulin production plant in the City of Montes Claros, Brazil.

The plant, which will be dedicated to formulation, filling and packaging of insulin products, will be built to GMP standards and will be able to supply export markets around the world. Approximately 500 jobs will be created.

Building will start in first half of 2004 with the aim of starting production in 2007. The investment follows Novo Nordisk's acquisition of Biobras, a local Brazilian insulin producer, and reflects its commitment to the Latin American market. Earlier this year, Novo Nordisk expanded the insulin production capacity of Biobras' plant in Montes Claros by 60%. Furthermore, the plant will soon start packaging of NovoNorm - a tablet for type 2 diabetes - for export to countries in Latin America, Asia and Europe.

'I believe this will be the largest investment ever by a foreign pharmaceutical company in Brazil,' said Sergio Noschang, Novo Nordisk's vice president in charge of the company's operations in Latin America and the Caribbean. 'It will not only lead to a ten-fold increase of our current production capacity but also bring know-how on biotechnology and pharmaceutical production to the country.'

  

  • Companies:
  • Novo Nordisk Pharmatech
See more

You may also like

Regulatory

Novo Nordisk’s oral semaglutide scores EU approval for cardiovascular benefits

Read more
Rybelsus is now the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Abselion launches AAVX and AAV9 Total Capsid Quantification Kits Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes
  3. diaago and Peak Analysis & Automation partner to bring practical automation solutions to research laboratories Using diaago's customer-first approach with PAA’s decades of expertise in laboratory robotics, the collaboration promises to deliver solutions to streamline workflows, boost throughput and reduce bottlenecks
  4. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  5. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Regulatory

Novo Nordisk’s oral semaglutide scores EU approval for cardiovascular benefits

Rybelsus is now the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Research & Development

Wegovy cuts risk of heart attack, stroke or death by 57% compared with tirzepatide

Study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy are specific to the semaglutide molecule and therefore cannot be extended to other GLP-1 or GIP/GLP-1-based treatments
Drug Delivery

BioMed X and Novo Nordisk launch new collaboration in oral peptide drug delivery

The initiative aims to identify and support new ideas for innovative oral formulations for peptide drugs such as GLP-1 receptor agonists via BioMed X’s global talent sourcing and incubation model

Wegovy approved by FDA to treatment adults with non-cirrhotic MASH with moderate to advanced liver fibrosis

The FDA has granted approval for Wegovy (semaglutide) injection 2.4 mg as the first GLP-1 receptor agonist to treat adults with moderate to advanced liver scarring because of MASH, marking a significant advancement in the management of this serious condition
Research & Development

Novo Nordisk's Wegovy effective in obese patients, Phase IIIb data suggests

A 7.2mg dose of semaglutide triggered an average weight loss of 21% in obese patients during a 72 week period
Finance

Weight loss drugs fuelling rapid big pharma growth, report reveals

Weight loss and diabetes medications are championing growth in key big pharma players, such as Novo Nordisk and Eli Lilly
Finance

Novo Holdings completes acquisition of Catalent

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
Subscribe now